Exelixis lands PhIII kidney cancer win with Bristol Myers in their hunt for $4 billion
Three months after CEO Michael Morrissey casually tossed a $4 billion peak sales figure for his company at the JP Morgan Healthcare Conference, Exelixis is one step closer to that lofty goal, celebrating a pivotal trial win today with Bristol Myers Squibb.
In combination with the pharma giant’s checkpoint inhibitor Opdivo, Exelixis’ once-daily pill Cabometyx improved progression-free survival and overall survival in patients with renal cell carcinoma, a form of kidney cancer. The Phase III trial tested the combo against an older drug, called sunitinib, in previously untreated patients. The new treatment reduced the risk of disease progression by 49% and of death by 40%, according to an Exelixis SEC filing.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,500+ biopharma pros reading Endpoints daily — and it's free.